ES3038614T3 - Oligomeric particle reagents and methods of use thereof - Google Patents

Oligomeric particle reagents and methods of use thereof

Info

Publication number
ES3038614T3
ES3038614T3 ES18737405T ES18737405T ES3038614T3 ES 3038614 T3 ES3038614 T3 ES 3038614T3 ES 18737405 T ES18737405 T ES 18737405T ES 18737405 T ES18737405 T ES 18737405T ES 3038614 T3 ES3038614 T3 ES 3038614T3
Authority
ES
Spain
Prior art keywords
streptavidin
oligomeric particle
binding
cases disclosed
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18737405T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Schmidt
Christian Stemberger
Tom Kowski
Ken Prentice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Juno Therapeutics Inc
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Application granted granted Critical
Publication of ES3038614T3 publication Critical patent/ES3038614T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4526—Corynebacterium or Propionibacterium, Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium or Gardnerella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Sustainable Development (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES18737405T 2017-04-27 2018-04-27 Oligomeric particle reagents and methods of use thereof Active ES3038614T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491245P 2017-04-27 2017-04-27
PCT/IB2018/000507 WO2018197949A1 (en) 2017-04-27 2018-04-27 Oligomeric particle reagents and methods of use thereof

Publications (1)

Publication Number Publication Date
ES3038614T3 true ES3038614T3 (en) 2025-10-14

Family

ID=62816880

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18737405T Active ES3038614T3 (en) 2017-04-27 2018-04-27 Oligomeric particle reagents and methods of use thereof

Country Status (16)

Country Link
US (2) US11866465B2 (enExample)
EP (2) EP3615653B1 (enExample)
JP (2) JP7339160B2 (enExample)
KR (2) KR102606210B1 (enExample)
CN (1) CN111032850B (enExample)
AR (2) AR111625A1 (enExample)
AU (1) AU2018260380B2 (enExample)
BR (1) BR112019022356A2 (enExample)
CA (1) CA3060526A1 (enExample)
ES (1) ES3038614T3 (enExample)
IL (1) IL270142B2 (enExample)
MA (1) MA49288A (enExample)
PH (1) PH12019502415A1 (enExample)
SG (1) SG11201909931PA (enExample)
TW (1) TW201842335A (enExample)
WO (1) WO2018197949A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
LT3132247T (lt) 2014-04-16 2021-12-10 Juno Therapeutics Gmbh Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės
JP6692834B2 (ja) 2015-02-09 2020-05-13 スリングショット バイオサイエンシーズ， インコーポレイテッド 調整可能な光学特性を有するヒドロゲル粒子およびその使用の方法
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
CN108474791B (zh) 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
CA3084445A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
JP7604366B2 (ja) 2018-11-06 2024-12-23 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作されたｔ細胞を作製するための方法
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
KR20220122642A (ko) * 2019-11-27 2022-09-02 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 T 세포의 대규모 조합된 car 형질 도입 및 crispr 유전자 편집
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
IL295381B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
IL295384B1 (en) 2020-02-12 2026-04-01 Juno Therapeutics Inc T-cell preparations with chimeric antigen receptor directed against CD19 and methods and uses thereof
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
EP4230643A4 (en) * 2020-10-16 2025-04-02 Sysmex Corporation POLYPEPTIDE, POLYMER, SOLID PHASE, MEASURING METHOD FOR TEST SUBSTANCE, AND REAGENT KIT
CN112552415B (zh) * 2021-02-22 2021-06-22 北京百普赛斯生物科技股份有限公司 B淋巴细胞刺激因子十二聚体及其制备方法与应用
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
EP4423250A1 (en) 2021-10-29 2024-09-04 Slingshot Biosciences, Inc. Hydrogel particles as feeder cells and as synthetic antigen presenting cells
WO2023147510A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Chromatography arrays and related methods and kits
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023215886A1 (en) 2022-05-05 2023-11-09 Slingshot Biosciences, Inc. Engineered particles as red blood cell mimics and compositions containing same for hematology
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
CN120712108A (zh) 2022-10-26 2025-09-26 弹弓生物科学公司 具有可调整光学性质的大小可调整合成颗粒和用于使用其进行免疫细胞激活的方法
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
WO2024182516A1 (en) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
WO2024186668A2 (en) * 2023-03-07 2024-09-12 Slingshot Biosciences, Inc. Size-tunable synthetic particles for immune cell activation
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
WO2025049250A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 6,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049247A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 5,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049254A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
CN122029170A (zh) 2023-08-25 2026-05-12 朱诺治疗学股份有限公司 基于桥环的dna依赖性蛋白激酶抑制剂和组合物及其在基因编辑中的应用
CN121986254A (zh) 2023-08-29 2026-05-05 弹弓生物科学公司 Cd34干细胞模拟物
WO2025160395A1 (en) 2024-01-25 2025-07-31 Juno Therapeutics, Inc. Use of bridged cycle-based inhibitors of dna-dependent protein kinase in combination of dna polymerase theta inhibitor and compositions and application in gene editing
WO2025179188A1 (en) 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing
TW202605143A (zh) 2024-05-10 2026-02-01 美商奇諾治療有限公司 表現cd19嵌合抗原受體(car)之基因工程化t細胞及其用於同種異體細胞療法之用途
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses
WO2026050426A2 (en) 2024-08-28 2026-03-05 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2467434A (en) 1947-05-10 1949-04-19 Air Associates Inc Servomotor and pressure responsive valve therefor
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3583940D1 (de) 1984-10-02 1991-10-02 Harry M Meade Herstellung von streptavidinaehnlichen polypeptiden.
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
GB9215540D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
WO1994029436A1 (en) 1993-06-04 1994-12-22 The United States Of America Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
EP0997477B1 (en) 1994-07-29 2006-03-15 Sunol Molecular Corporation MHC complexes and uses thereof
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
WO1996024606A1 (en) 1995-02-09 1996-08-15 University Of Washington Modified-affinity streptavidin
AU5917796A (en) 1995-04-11 1997-04-09 Trustees Of Boston University Streptavidin mutants
US5629205A (en) 1995-05-19 1997-05-13 Allelix Biopharmaceuticals Inc. Promoters for gene expression
WO1997005266A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
AR005035A1 (es) 1995-12-11 1999-04-07 Merck Patent Ges Mit Beschränkter Haftung Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US5773224A (en) 1996-02-12 1998-06-30 Grandics; Peter Immunoselection system for cell elution
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
DE19637718A1 (de) 1996-04-01 1997-10-02 Boehringer Mannheim Gmbh Rekombinante inaktive Core-Streptavidin Mutanten
US6022688A (en) 1996-05-13 2000-02-08 Sequenom, Inc. Method for dissociating biotin complexes
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
ATE272070T1 (de) 1996-08-16 2004-08-15 Harvard College Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998040396A1 (en) 1997-03-14 1998-09-17 Trustees Of Boston University Multiflavor streptavidin
US6391571B1 (en) 1997-04-01 2002-05-21 Roche Diagnostics Gmbh Recombinant inactive avidin mutants
DK1017721T3 (da) 1997-09-16 2009-04-20 Univ Oregon Health & Science Rekombinante MHC molekyler, der kan anvendes til manipulation af antigenspecifikke T-celler
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
WO1999042597A1 (en) 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
ES2330017T3 (es) 1998-05-23 2009-12-03 Leiden University Medical Center Ligandos de cd40 y peptidos de ctl para tratar tumores.
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6664042B1 (en) 1999-01-26 2003-12-16 Cornell Research Foundation, Inc. Determining viral load in double negative T cells
WO2000046349A1 (en) 1999-02-04 2000-08-10 Technion Research & Development Foundation Ltd. Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells
EP1048732A1 (de) 1999-04-26 2000-11-02 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von natürlich gefalteten und sekretierten Proteinen
US6849185B1 (en) 1999-05-14 2005-02-01 Pall Corp Charged membrane
DE60027291T2 (de) 1999-05-14 2007-01-18 Pall Corp. Elektrisch geladene membran
EP1669129A1 (en) 1999-05-14 2006-06-14 Pall Corporation Charged membrane
ATE458818T1 (de) 1999-06-07 2010-03-15 Tet Systems Holding Gmbh & Co Tet repressor basierte transkriptionale regulatorische proteine
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
AU2001236621B2 (en) 2000-02-01 2006-06-15 Mycenax Biotech Inc. Cd40-binding apc-activating molecules
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2001081371A1 (en) 2000-04-25 2001-11-01 Otsuka Pharmaceutical Co., Ltd. Gd3-mimetic peptides
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US6638728B1 (en) 2000-06-16 2003-10-28 Pierce Biotechnology, Inc. Coated surfaces with high capacity for capturing target molecules
CA2426100A1 (en) 2000-11-03 2002-05-23 Genentech, Inc. Metabolic rate shifts in fermentations expressing recombinant proteins
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
WO2002055992A2 (en) 2001-01-12 2002-07-18 Becton Dickinson Co Intrinsically fluorescent, self-multimerizing mhc fusion proteins and complexes thereof
GB0102568D0 (en) 2001-02-01 2001-03-21 Magnetic Biosolutions Sweden A Method
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
EP2011802A3 (en) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
CN100513414C (zh) 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的系统
EP1908769A1 (en) 2001-08-27 2008-04-09 Genentech, Inc. A system for antibody expression and assembly
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
JP2005536184A (ja) 2002-03-01 2005-12-02 エルドマン，ヴォルカー，エー． ストレプトアビジン結合ペプチド
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7754155B2 (en) 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
AU2003234194A1 (en) 2002-04-23 2003-11-10 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
JP4659453B2 (ja) 2002-06-24 2011-03-30 ハイグロス・インヴェスト・ゲゼルシャフト・ミット・ベシュレンクトル・ハフツング エンドトキシンを検出および除去する方法
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
JP4726483B2 (ja) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
CA2500392C (en) 2002-09-27 2012-11-27 The General Hospital Corporation Microfluidic device for cell separation and uses thereof
EP1588166A4 (en) 2003-01-09 2007-06-27 Macrogenics Inc VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2004096975A2 (en) 2003-05-02 2004-11-11 Insception Bioscience, Inc. Apparatus and methods for amplification of blood stem cell numbers
DE60334250D1 (de) 2003-05-08 2010-10-28 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t-zellen
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
WO2005017174A2 (en) 2003-08-13 2005-02-24 Sandoz Ag Process for the purification of recombinant polypeptides
GB0319601D0 (en) 2003-08-20 2003-09-24 Sandoz Ag Production process
GB0321100D0 (en) 2003-09-09 2003-10-08 Celltech R&D Ltd Biological products
GB2408507B (en) 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
KR100570422B1 (ko) 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
WO2005050209A1 (en) 2003-11-20 2005-06-02 Biosensor Applications Sweden (Publ) Mixture of at least two different antibodies specific for predetermined antigens and use of the mixture
CN1882605B (zh) 2003-11-21 2012-07-11 陶氏环球技术公司 使用Sec-系统分泌的改进的表达系统
SE0400181D0 (sv) 2004-01-29 2004-01-29 Gyros Ab Segmented porous and preloaded microscale devices
ES2527291T3 (es) 2004-03-11 2015-01-22 Genentech, Inc. Proceso para la producción de polipéptidos
US7776583B2 (en) 2004-06-03 2010-08-17 Meso Scale Technologies, Llc Methods and apparatuses for conducting assays
JP5255841B2 (ja) 2004-10-15 2013-08-07 ジェネンコー・インターナショナル・インク 競合示差スクリーニング
WO2006058226A2 (en) 2004-11-24 2006-06-01 The Trustees Of Boston University Modified dimeric streptavidins and uses thereof
US20060252087A1 (en) 2005-01-18 2006-11-09 Biocept, Inc. Recovery of rare cells using a microchannel apparatus with patterned posts
US20110027220A1 (en) 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
US7704708B2 (en) 2006-02-13 2010-04-27 Uti Limited Partnership Monomeric streptavidin muteins
US7855057B2 (en) 2006-03-23 2010-12-21 Millipore Corporation Protein splice variant/isoform discrimination and quantitative measurements thereof
WO2007117602A2 (en) 2006-04-07 2007-10-18 Biogen Idec Ma Inc. Isolation and use of human regulatory t cells
GB2442048B (en) 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
US20080085532A1 (en) 2006-09-18 2008-04-10 Jorn Gorlach Method for determining the immune status of a subject
DK1905839T4 (da) 2006-09-22 2019-10-07 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af proteiner
DE102006044841A1 (de) 2006-09-22 2008-04-03 Wacker Chemie Ag Signalpeptid zur Produktion von rekombinanten Proteinen
EP1903105B1 (de) 2006-09-22 2010-04-21 Wacker Chemie AG Verfahren zur fermentativen Herstellung von Proteinen
DK1903115T3 (da) 2006-09-22 2011-05-23 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af antistoffer
EP2687540A1 (en) 2006-10-17 2014-01-22 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
EP2085782B1 (en) 2006-11-02 2017-03-08 Kyowa Medex CO., LTD. Method of immunoassaying a component to be measured
EP2518193A3 (en) 2006-11-15 2013-01-23 Invitrogen Dynal AS Methods for reversibly binding a biotin compound to a support
CN101226118B (zh) 2007-01-19 2010-06-16 中国医学科学院肿瘤研究所 一种兼容免疫荧光分析的细胞化学染色方法及其用途
CA2677179C (en) 2007-01-31 2016-02-16 Dow Global Technologies Inc. Bacterial leader sequences for increased expression
KR20080076622A (ko) 2007-02-16 2008-08-20 포항공과대학교 산학협력단 올리고머화된 단백질 전달체와 이를 이용한 세포내바이러스 벡터 전달 방법
US8709980B2 (en) 2007-03-26 2014-04-29 Celexion, Llc Cell surface display, screening and production of proteins of interest
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
PL2856876T3 (pl) 2007-03-30 2018-06-29 Memorial Sloan-Kettering Cancer Center Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
CN101802195B (zh) 2007-08-20 2012-10-24 内克斯特伊拉股份公司 pⅦ噬菌体展示
ES2319061B1 (es) 2007-09-11 2010-02-10 Biomedal, S.L. Metodo de conservacion de peptidos o proteinas.
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
EP3358354B1 (en) 2008-01-18 2020-07-15 President and Fellows of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
CN106986926A (zh) 2008-01-30 2017-07-28 皮里斯股份公司 具有对人c‑met受体酪氨酸激酶的亲和性的泪脂质运载蛋白的突变蛋白及其获得方法
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
CN101446576B (zh) 2008-12-29 2011-06-22 江苏省苏微微生物研究有限公司 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法
WO2010080032A2 (en) 2009-01-09 2010-07-15 Stichting Het Nederlands Kanker Instituut Bead-assisted viral transduction
DE102009018647A1 (de) 2009-04-23 2010-10-28 Osram Opto Semiconductors Gmbh Strahlungsemittierende Vorrichtung
US20110070581A1 (en) 2009-04-27 2011-03-24 Amit Gupta Separation of Leukocytes
WO2011053971A2 (en) 2009-11-02 2011-05-05 Fina Biosolutions, Llc Method for enhancing the sensitivity of antibody based assays
SI2496601T1 (sl) 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Tehnike in sestavek za sekrecijo heterolognih polipeptidov
US8450086B2 (en) 2009-11-17 2013-05-28 Centocor Ortho Biotech Inc. Bacterial membrane protein secretion
US20120321665A1 (en) 2009-12-14 2012-12-20 Benaroya Research Institute At Virginia Mason Compositions and methods for treating airway inflammatory diseases
US9370732B2 (en) 2013-02-15 2016-06-21 Douglas T. Gjerde Methods for purifying biological cells
US9637719B2 (en) 2013-12-06 2017-05-02 Douglas T. Gjerde Devices and methods for purification of biological cells
US9891148B2 (en) 2010-02-09 2018-02-13 Douglas T. Gjerde Method and apparatus for pipette tip columns
US9242244B2 (en) 2010-02-09 2016-01-26 Douglas T. Gjerde Method and apparatus for pipette tip columns
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
EP2363501A1 (en) 2010-03-02 2011-09-07 Universitätsklinikum Hamburg-Eppendorf Method for isolating target cells
JP5665021B2 (ja) 2010-03-08 2015-02-04 国立大学法人東京農工大学 融合ｍｈｃ分子連結磁気微粒子、抗原ペプチドのスクリーニング方法、組換えベクター、及び磁性細菌の形質転換体
WO2011161086A2 (en) 2010-06-23 2011-12-29 Stobbe Tech. A/S Device and method for industrial cultivation of cells
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
US9410157B2 (en) 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
EP2982766B1 (en) 2010-08-06 2018-05-23 Ludwig-Maximilians-Universität München Identification of t cell target antigens
US10023657B2 (en) 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
WO2012058627A2 (en) 2010-10-29 2012-05-03 Miqin Zhang Pre-targeted nanoparticle system and method for labeling biological particles
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
JP5840857B2 (ja) 2011-04-08 2016-01-06 国立大学法人 東京大学 細胞傷害性ｔ細胞誘導用組成物
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US9023604B2 (en) 2011-07-18 2015-05-05 Iba Gmbh Method of reversibly staining a target cell
WO2013038272A2 (en) 2011-09-13 2013-03-21 Uti Limited Partnership Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins
US10208086B2 (en) 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
CN112375846A (zh) 2012-07-13 2021-02-19 宾夕法尼亚大学董事会 评估用于施用的转导t细胞的适用性的方法
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
WO2014039044A1 (en) 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t memory stem cell populations
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
SG11201502598SA (en) 2012-10-02 2015-05-28 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy
CA2891820A1 (en) * 2012-11-16 2014-05-22 Iba Gmbh Streptavidin muteins and methods of using them
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
EP2951192A1 (en) 2013-01-31 2015-12-09 Glaxo Group Limited Method of producing a protein
US10220332B2 (en) 2013-02-15 2019-03-05 Douglas T. Gjerde Columns for isolation, detection and use of biological cells
US9920294B2 (en) 2013-02-15 2018-03-20 Douglas T. Gjerde Devices and methods for purification, detection and use of biological cells
US10107729B2 (en) 2013-02-15 2018-10-23 Douglas T. Gjerde Isolation, detection and use of biological cells
CN103305464B (zh) 2013-06-05 2015-04-15 南昌大学 直接分离cd4+和cd8+淋巴细胞的方法
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
AU2014368892B2 (en) 2013-12-20 2019-06-13 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
LT3132247T (lt) * 2014-04-16 2021-12-10 Juno Therapeutics Gmbh Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės
IL313845A (en) 2014-04-23 2024-08-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
WO2015162211A1 (en) 2014-04-24 2015-10-29 Miltenyi Biotec Gmbh Method for automated generation of genetically modified t cells
WO2015166049A1 (en) 2014-04-30 2015-11-05 Iba Gmbh Method of isolating a target cell
EP3511413B1 (en) 2014-07-25 2022-09-07 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
WO2016166568A1 (en) * 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
CN108474791B (zh) 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
HK1258932A1 (zh) * 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
US11466253B2 (en) 2015-10-22 2022-10-11 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
CN108884140B (zh) 2015-12-03 2022-10-25 朱诺治疗学股份有限公司 修饰的嵌合受体及相关组合物和方法
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
US20190247846A1 (en) 2018-02-09 2019-08-15 Chris Suh Method and Apparatus for Pipette Tip Columns
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法

Also Published As

Publication number Publication date
AR111625A1 (es) 2019-07-31
KR20200019126A (ko) 2020-02-21
IL270142B1 (en) 2025-01-01
TW201842335A (zh) 2018-12-01
RU2019138171A (ru) 2021-05-27
JP7339160B2 (ja) 2023-09-05
AR127020A2 (es) 2023-12-13
US11866465B2 (en) 2024-01-09
BR112019022356A2 (pt) 2020-05-26
IL270142B2 (en) 2025-05-01
KR20230164219A (ko) 2023-12-01
US20210032297A1 (en) 2021-02-04
NZ758485A (en) 2024-02-23
JP2020517705A (ja) 2020-06-18
CA3060526A1 (en) 2018-11-01
PH12019502415A1 (en) 2020-09-14
EP4647493A2 (en) 2025-11-12
JP2023159346A (ja) 2023-10-31
EP3615653B1 (en) 2025-07-23
MA49288A (fr) 2020-03-04
CN111032850B (zh) 2024-08-13
SG11201909931PA (en) 2019-11-28
EP3615653A1 (en) 2020-03-04
KR102606210B1 (ko) 2023-11-24
WO2018197949A1 (en) 2018-11-01
RU2019138171A3 (enExample) 2022-01-24
US20240101613A1 (en) 2024-03-28
AU2018260380A1 (en) 2019-11-07
CN111032850A (zh) 2020-04-17
IL270142A (enExample) 2019-12-31
AU2018260380B2 (en) 2025-02-13
EP4647493A3 (en) 2026-01-14

Similar Documents

Publication Publication Date Title
US20240101613A1 (en) Oligomeric particle reagents and methods of use thereof
US20230295567A1 (en) Methods for culturing cells and kits and apparatus for same
US20240191188A1 (en) Methods for culturing cells and kits and apparatus for same
KR102912482B1 (ko) 세포의 선택 및 자극을 위한 방법 및 이를 위한 장치
JP2018531035A6 (ja) 細胞を培養するための方法ならびにそのためのキットおよび装置
RU2777989C2 (ru) Олигомерные реагенты в виде частиц и способы их применения
BR112018008081B1 (pt) Método para cultura de células t, artigo de fabricação e kit